Form 4: Artiva Biotherapeutics CFO Neha Krishnamohan Reports Stock Award and Disposal
SEC Form 4 Filing
Neha Krishnamohan, CFO of Artiva Biotherapeutics, reports the acquisition of 60,000 shares of common stock and disposal of 110,000 shares.
Summary
- On February 26, 2025, Neha Krishnamohan, the Chief Financial Officer of Artiva Biotherapeutics, reported a transaction involving the company's common stock.
- Krishnamohan acquired 60,000 shares of common stock.
- These shares were acquired at a price of $0.
- Krishnamohan also disposed of 110,000 shares.
- Following these transactions, Krishnamohan still beneficially owns common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard reporting of stock transactions. The disposal of shares is balanced by the acquisition of shares.
Positives
- The acquisition of 60,000 shares indicates continued investment in the company by the CFO.
Negatives
- The disposal of 110,000 shares by the CFO could be interpreted negatively by investors.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to the market.
Key Dates
| Date | Description |
|---|---|
| 02/26/2025 | Date of stock acquisition and disposal. |
| 02/27/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.